Suga Yukio, Kitade Hironori, Kawagishi Atsufumi, Takeda Kazuyoshi, Haruki Kazunobu, Ishizaki Junko, Sai Yoshimichi, Kasahara Kazuo, Arai Kunizo, Miyamoto Ken-ichi
Institute of Medical, Pharmaceutical & Health Science, Kanazawa University.
Gan To Kagaku Ryoho. 2011 Dec;38(13):2617-21.
Because it is considered that there is a close connection between gustation and olfactation, and that a decline in the function of either sensation influences the other one, it would be useful to clarify the relation between gustatory and olfactory disorders in patients receiving cancer chemotherapy. Therefore, we investigated the frequency of gustatory and olfactory disorders in patients administered anticancer drugs at the Division of Outpatient Chemotherapy of Kanazawa University. Among 136 patients who consented to participate in the investigation, 75 patients (55%) complained of a gustatory disorder, and 26 patients (19%) complained of an olfactory disorder. The occurrences of olfactory disorder were significantly greater in patients who had gustatory disorder than in patients who did not. The expression frequency of gustatory disorders was significantly higher among those taking docetaxel (85%) when compared with patients on other regimens. Although not statistically significant, the incidence of olfactory disorder was higher in patients taking docetaxel (31%), irinotecan+l-leucovorin (l-LV)+5-fluorouracil (5-FU) (31%), l-oxaliplatin+l-LV+5-FU (28%), trastuzumab (23%), and weekly paclitaxel (22%). Medical staff should recognize that olfactory disorders are similar to gustatory disorders, as they both have adverse reactions induced by anticancer drugs.
由于人们认为味觉和嗅觉之间存在密切联系，且任何一种感觉功能的下降都会影响另一种感觉，因此阐明接受癌症化疗患者的味觉和嗅觉障碍之间的关系将是有益的。因此，我们在金泽大学门诊化疗科对接受抗癌药物治疗的患者的味觉和嗅觉障碍发生率进行了调查。在136名同意参与调查的患者中，75名患者（55%）抱怨有味觉障碍，26名患者（19%）抱怨有嗅觉障碍。有味觉障碍的患者中嗅觉障碍的发生率显著高于没有味觉障碍的患者。与接受其他治疗方案的患者相比，服用多西他赛的患者（85%）味觉障碍的表达频率显著更高。虽然无统计学意义，但服用多西他赛（31%）、伊立替康+亚叶酸钙（l-LV）+5-氟尿嘧啶（5-FU）（31%）、l-奥沙利铂+l-LV+5-FU（28%）、曲妥珠单抗（23%）和每周一次紫杉醇（22%）的患者嗅觉障碍的发生率更高。医务人员应认识到嗅觉障碍与味觉障碍相似，因为它们都是由抗癌药物引起的不良反应。
